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Artesunate Protects Against the Organ Injury and
Dysfunction Induced by Severe Hemorrhage and Resuscitation
Regina Sordi, PhD, Kiran K. Nandra, PhD, Fausto Chiazza, BSc,y Florence L. Johnson, BSc,
Claudia P. Cabrera, PhD,z Hew D. Torrance, MD,§ Noriaki Yamada, MD, PhD, Nimesh S. A. Patel, PhD,
Michael R. Barnes, PhD,z Karim Brohi, MD,§ Massimo Collino, PhD,y and Christoph Thiemermann, MD, PhD
Objective: To evaluate the effects of artesunate on organ injury and dys-
function associated with hemorrhagic shock (HS) in the rat.
Background: HS is still a common cause of death in severely injured patients
and is characterized by impairment of organ perfusion, systemic inflamma-
tory response, and multiple organ failure. There is no specific therapy that
reduces organ injury/dysfunction. Artesunate exhibits pharmacological
actions beyond its antimalarial activity, such as anticancer, antiviral, and
anti-inflammatory effects.
Methods: Rats were submitted to HS. Mean arterial pressure was reduced to
30mm Hg for 90minutes, followed by resuscitation. Rats were randomly
treated with artesunate (2.4 or 4.8mg/kg i.v.) or vehicle upon resuscitation.
Four hours later, parameters of organ injury and dysfunction were assessed.
Results: Artesunate attenuated the multiple organ injury and dysfunction
caused by HS. Pathway analysis of RNA sequencing provided good evidence
to support an effect of artesunate on the Akt-survival pathway, leading to
downregulation of interleukin-1 receptor-associated kinase 1. Using Western
blot analysis, we confirmed that treatment of HS rats with artesunate
enhanced the phosphorylation (activation) of Protein kinase B (Akt) and
endothelial nitric oxide synthase and the phosphorylation (inhibition) of
glycogen synthase kinase-3b (GSK-3b). Moreover, artesunate attenuated
the HS-induced activation of nuclear factor kappa B and reduced the
expression of proinflammatory proteins (inducible nitric oxide synthase,
tumor necrosis factor-a, and interleukin 6).
Conclusions: Artesunate attenuated the organ injury/dysfunction associated
with HS by a mechanism that involves the activation of the Akt-endothelial
nitric oxide synthase survival pathway, and the inhibition of glycogen
synthase kinase-3b and nuclear factor kappa B. A phase II clinical trial
evaluating the effects of good manufacturing practice-artesunate in patients
with trauma and severe hemorrhage is planned.
Keywords: Akt, antimalarial, artesunate, hemorrhagic shock, interleukin-1
receptor-associated kinase 1, nuclear factor kappa B, organ injury
(Ann Surg 2017;265:408–417)
T rauma is a leading cause of death with 5 million of victims yearly.About 40% of trauma deaths are due to hemorrhagic shock (HS),
which causes hypoperfusion of organs leading to multiple organ
failure (MOF).1 MOF occurs in 30% of injured patients, and it is the
major cause of morbidity after trauma.2 MOF correlates with an
increase in nosocomial infections and, if it persists, mortality.3 The
mechanisms underlying MOF are not fully understood, but ischemia-
reperfusion injury and systemic inflammation are key players.4
Although there are clear guidelines for the management of HS
and organ support strategies, there is no specific pharmacological
intervention that prevents the MOF associated with HS. Thus, a
therapeutic agent that reduces the incidence and/or severity of MOF
is urgently needed and could have major global impact on patient
outcomes.
Artesunate (a semisynthetic artemisinin derived from Arte-
misia annua) is recommended by the World Health Organization as
the treatment of choice for severe malaria.5 Artesunate is a safe, low-
cost drug, which has been used by thousands of patients with malaria
without important adverse effects.6 Although the mechanism behind
the antimalarial activity of artesunate is not entirely clear, it is
thought that the active metabolite, dihydroartemisinin is responsible
for the death of the parasite.7
Artemisinins, including artesunate, have many pharmacologi-
cal effects beyond the eradication of Plasmodium.8 Artemisinins/
artesunate are cytotoxic against cancer cells,9 viruses,10 fungi,11 but
also exert powerful anti-inflammatory effects in experimental
asthma,12 pancreatitis,13 arthritis,14 and sepsis15. The effects of
artesunate in HS are unknown. Therefore, the aim of the present
study was to investigate the effects of artesunate on the organ injury/
dysfunction associated with HS. Having discovered that artesunate
attenuates the MOF associated with HS, we have investigated the
potential mechanism of action of artesunate, including RNA-seq
transcriptomics and pathway analysis. We report here for the first
time that artesunate has prosurvival and anti-inflammatory
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properties, as it activates the Akt-endothelial nitric oxide synthase
(eNOS) cell survival pathway and inhibits a range of proinflamma-
tory molecules, including interleukin-1 receptor-associated kinase 1
(IRAK1), forkhead box O4 (FOXO4), glycogen synthase kinase-3b
(GSK-3b), and the transcription factor nuclear factor kappa B (NF-kB).
METHODS
Animal Welfare and Ethical Statements
The animal protocols used in this study were approved by the
Animal Welfare Ethics Review Board of Queen Mary University of
London (PPL: 70/7348) in accordance with Home Office guidance on
Operation of Animals (Scientific Procedures Act 1986) and Guide for
Care andUse of LaboratoryAnimals of the National Research Council.
Hemorrhagic Shock and Quantification of Organ
Injury
This study was carried out on 120 male Wistar rats (Charles
River Ltd, UK) weighing 280 g receiving a standard diet and water
ad libitum. HS was performed as previously described.16 Rats were
anesthetized using sodium thiopentone (120mg/kg i.p. maintained
using 10mg/kg i.v.). Blood was withdrawn to achieve a fall in mean
arterial pressure (MAP) to 30 2 mm Hg, which was maintained for
a period of 90 minutes. At 90 minutes after initiation of hemorrhage
(or when 25% of the shed blood had to be reinjected to sustain MAP
at 30 mmHg), resuscitation was performed with the (remaining) shed
blood over a period of 5 minutes. The same volume of blood
reinfused for maintenance of MAP was replaced by Ringer lactate
on resuscitation. An infusion of Ringer Lactate (1.5mL/kg/hour; i.v.)
was maintained throughout the experiment for a total of 4 hours. The
last 3 hours urine was obtained for the estimation of creatinine
clearance. Blood was collected for the measurement of lactate
(Accutrend Plus Meter, Roche Diagnostics, UK) and organ injury
parameters (IDEXX Ltd, UK). Samples were taken and stored at
80oC. Sham rats were used as control and underwent identical
surgical procedures, but without hemorrhage/resuscitation.
Experimental Design
Rats were randomly allocated into the following groups (n ¼
10 per group): sham þ vehicle; sham þ artesunate 4.8mg/kg; HS þ
vehicle; HS þ artesunate 2.4mg/kg and HS þ artesunate 4.8mg/kg.
Artesunate was diluted in phosphate buffer (vehicle; NaH2PO4
18.3mM; Na2HPO4 150.4mM; pH 7.9–8.1). Rats were administered
vehicle (1mL/kg) or artesunate (2.4mg/mL/kg or 4.8mg/mL/kg) i.v.
upon resuscitation. We have performed a previous study designed to
evaluate the effects of artesunate (1, 3, and 10mg/kg; supplemental
Fig. 1, http://links.lww.com/SLA/A977) in HS. The maximal
reduction in organ injury/dysfunction was reached with a dose of
3mg/kg. To increase the clinical relevance (and potentially the
ability to translate our preclinical findings to a clinical trial), we
have then evaluated the effects of 2.4mg/kg of artesunate in HS, as
this dose is given to patients with severe malaria. We have also
investigated a higher dose of artesunate (4.8mg/kg).
Determination of Myeloperoxidase Activity
Myeloperoxidase (MPO) activity was performed as previously
described.16
RNA sequencing Analysis
Gene expressionwas evaluated byRNA sequencing (RNA-seq)
that allows a dynamic range of detection andmeasurement of relatively
limited differences in expression between samples. The transcriptomic
analysis included a normalization procedure that should correct for
differential RNAyields between samples. Whole blood RNA samples
were extracted from 12 rats (3 samples per group). One microgram of
total RNAwas used for library preparation, according to the Illumina
TruSeq mRNA sample preparation protocol (Illumina, San Diego,
CA). Libraries were sequenced using Illumina NextSeq platform and
TruSeq protocol. Adaptor and poor quality sequences were removed
using trim galore (v 0.3.7) software, Babraham, Cambridgeshire, UK.
Trimmed sequences were aligned to the rat reference genome (rnor5)
withTopHat2 (v2.0.13)/bowtie2 (v2.2.3),Baltimore,MD.Read counts
were calculated using the HTSeq-counts program and differential
expression analyses were carried out with DESeq2, using the standard
protocols. Pathway analysis was performed using Enrichr17 and
Ingenuity Pathway Analysis.
Western Blot
Western blot was performed as previously described.16 The
densitometric analysis was performed using Gel Pro Analyzer 4.5,
2000 software (Media Cybernetics, Silver Spring, MD) and is
expressed as relative optical density, corrected for the corresponding
b-actin or histone H3 contents, and normalized using the related
mean sham-operated band.
Immunostaining for 3-Nitrotyrosine
Immunostaining was performed using anti-3-nitrotyrosine (3-
NT) antibody (1:2000; Merck Millipore, Germany) and the kit Dako
EnVision þ System-HRP-DAB. The quantification of immunostain-
ing was achieved through densitometry analysis of 10 random fields
of each sample using NIH ImageJ 1.36 imaging software (NIH,
Bethesda, MD).
Cytokines
Serum cytokines tumor necrosis factor (TNF)-a and interleukin
(IL)-6 were determined using commercial immunoassay kits (R&D
Systems, Minneapolis, MN) according to the manufacturer protocol.
Materials
Unless otherwise stated, all compounds were from Sigma-
Aldrich Company Ltd (Poole, Dorset, UK). Ringer’s Lactate was
from Baxter Healthcare Ltd (Deerfield, IL); sodium thiopentone
(Thiovet) from Link Pharmaceuticals, Horsham, UK. The bicincho-
ninic acid protein assay kit and SuperBlock blocking buffer were
from Thermo Fisher Scientific Inc (Rockford, IL). Antibodies were
from Cell Signalling Technology Inc (Beverly, MA).
Data Analysis
All figures are expressed as box-and-whisker format showing
medians, interquartile range, and full range. The tables are showing
minimun, 25% percentile, median, 75% percentile and maximum
values. Statistical analysis was carried out using GraphPad Prism
5.03 (GraphPad Software, La Jolla, CA). Data were assessed by 1 or
2-way analysis of variance followed by Bonferroni test. The distri-
bution of the data was verified by Kolmogorov-Smirnov test, and the
homogeneity of variances by Bartlett test. When necessary, values
have been transformed into logarithmic values to achieve normality
and homogeneity of variances. The data that were not normally
distributed were analyzed with a nonparametric test (Kruskal-Wallis
followed by Dunn test). A P< 0.05 was considered to be significant.
RESULTS
Artesunate Attenuates the Organ Injury and
Dysfunction Induced by HS
When compared to sham rats, rats subjected to HS exhibited a
decrease in creatinine clearance (Fig. 1A) and an increase in serum
creatinine (Fig. 1B) and, hence, renal dysfunction. HS rats also
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FIGURE 1. Artesunate attenuates the organ injury and dysfunction induced by HS. A, creatinine clearance; B, serum creatinine; C,
serum AST; D, serum alanine ALT; E; serum amylase; F, serum lipase; G, serum CK; and H, lactate of HS rats treated with vehicle or
artesunate (2.4 or 4.8mg/kg) on resuscitation are shown. Sham rats were treated with vehicle or artesunate 4.8mg/kg. Data are
presented as box and whiskers, showing medians, interquartile range, and full range (n ¼ 10 animals per group). When necessary
(as lipase data), the values had been transformed into logarithms to achieve normality and homogeneity of variances. Statistical
analysis was performed using 1-way ANOVA followed by Bonferroni post hoc test. P< 0.05 vs shamþ vehicle and #P< 0.05 vs HSþ
vehicle. ANOVA indicates analysis of variance; CK, creatine kinase.
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developed significant increases in serum aspartate aminotransferase
(Fig. 1C), serum alanine aminotransferase (Fig. 1D), serum amylase
(Fig. 1E), serum lipase (Fig. 1F), serum creatine kinase (Fig. 1G), and
lactate (Fig. 1H) indicating the development of liver, pancreas, and
neuromuscular injury, and global ischemia, respectively (Fig. 1).
When compared to HS rats treated with vehicle, treatment of
HS rats with 2.4mg/kg or 4.8mg/kg artesunate attenuated the fall in
creatinine clearance (Fig. 1A) and attenuated the rises in serum
creatinine (Fig. 1B), aspartate aminotransferase (Fig. 1C), and
creatine kinase (Fig. 1G). Treatment of HS rats with 4.8mg/kg
artesunate also significantly attenuated the HS-induced rise in serum
levels of alanine aminotransferase (Fig. 1D), amylase (Fig. 1E), and
lactate (Fig. 1H). No statistical difference was found between any of
the groups studied in serum glucose levels (supplemental Table 1,
http://links.lww.com/SLA/A977).
When compared to sham-operated rats, HS rats developed a
significant increase in lung MPO activity (Fig. 2) indicating lung
infiltration with inflammatory cells. Treatment of HS rats with both
doses of artesunate significantly attenuated the rise in MPO activity
in the lung (Fig. 2). Administration of high-dose artesunate to sham-
operated rats had no significant effect on any of the parameters
evaluated.
Artesunate Does Not Prevent the Development of
the Circulatory Failure Induced by HS
When compared to sham-operated rats (open circles), HS rats
treated with vehicle demonstrated a significant reduction in MAP
after resuscitation (P < 0.05; closed squares; Fig. 3). Administration
of artesunate (2.4 or 4.8mg/kg; closed triangles) on resuscitation
failed to attenuate the reduction in MAP caused by HS (Fig. 3) and
had no effect on MAP of sham rats (closed diamonds). Heart rate
(BPM) measurements of all groups of animals are shown in supple-
mental Table 2, http://links.lww.com/SLA/A977.
Artesunate Acts Predominantly on the AKT-survival
Pathway
RNA-seq transcriptome sequencing was performed on white
blood cells. In order to evaluate the key molecular drivers of the
observed differential expression in both sham and HS rats, we
evaluated enrichment of known protein–protein interaction hubs
using the Enrichr analysis tool (supplemental Fig. 2, http://link-
s.lww.com/SLA/A977). This identified, AKT1 protein interaction
as the consistently strongest protein–protein interaction enrichment
on a genome wide basis in both comparisons (10/119 AKT1 target
genes show differential expression; adjusted P ¼ 0.00116; supple-
mental Fig. 2, http://links.lww.com/SLA/A977, and supplemental
Table 3, http://links.lww.com/SLA/A977). The AKT1 interactor
genes identified in the analysis were PPM1A, IRAK1, AKT2,
ITGB3, LMNA, NCOA4, BPGM, FOXO4, BCL2L1, and CDC25B.
To investigate the possible mechanistic basis of AKT1 interaction
further, we constructed a mechanistic model of differentially
expressed direct AKT1 interactors using the molecule activity
predictor algorithm in Ingenuity PathwayAnalysis.18 The algorithm
predicted AKTactivation (Fig. 4), on the basis of downregulation of
a number of genes in the AKT core network that are known to be
downregulated by AKT, including IL-1 receptor-associated kinase 1
and forkhead box O4.
Artesunate Attenuates the Activation of NF-kB
Induced by HS
As artesunate may activate the Akt-survival pathway (Fig. 4),
and as organ protection by artesunate were observed in liver/kidney
(Fig. 1), we investigated the possible mechanisms by which arte-
sunate (4.8mg/kg) attenuated organ injury in liver/kidney. When
compared to sham rats, we found no significant differences in the
phosphorylation of Akt on Ser473 (Figs. 5A, 6A), eNOS on Ser1177
(Figs. 5B, 6B) or GSK-3b on Ser9 (Figs. 5C, 6C) in liver/kidney,
from HS rats treated with vehicle. HS rats, however, exhibited an
increase in the nuclear translocation of the p65 NF-kB subunit
(Figs. 5D, 6D). Treatment of HS rats with artesunate resulted in a
significant increase in the phosphorylation of Akt (Figs. 5A, 6A),
eNOS (Figs. 5B, 6B), GSK-3b (Figs. 5C, 6C), and attenuated the
translocation of the p65 NF-kB subunit to the nucleus (Figs. 5D,
6D). The treatment of sham rats with artesunate had no significant
effect (Figs. 5, 6).
FIGURE 2. Artesunate attenuates MPO activity in lungs
induced by HS. MPO activity in lungs of sham and HS rats
treated with vehicle or artesunate (2.4 or 4.8mg/kg) on resus-
citation are shown. Sham rats were treated with vehicle or
artesunate 4.8mg/kg. Data are presented as box and whiskers,
showing medians, interquartile range, and full range (n ¼ 5
animals per group). Statistical analysis was performed using 1-
way ANOVA followed by Bonferroni post hoc test. P < 0.05 vs
shamþ vehicle and #P< 0.05 vs HSþ vehicle. ANOVA indicates
analysis of variance.
FIGURE 3. Artesunate does not prevent the development of
the circulatory failure induced by HS. HS rats were treated with
vehicle or artesunate (2.4 or 4.8mg/kg) on resuscitation. Sham
animals were used as control and received vehicle or artesunate
(4.8mg/kg). The MAP was recorded during the whole exper-
iment. Data are expressed as mean  SD of 10 animals per
group. Statistical analysis was performed using 2-way ANOVA
followed by Bonferroni post hoc test. P < 0.05 sham vehicle vs
HS þ vehicle (not indicated in the figure). ANOVA indicates
analysis of variance; SD, standard deviation.
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Artesunate Reduces the iNOS Expression and
Cytokine Formation Induced by HS
As artesunate caused a decrease in the nuclear translocation of
p65 NF-kB, we also investigated the effects of artesunate on the
expression of NF-kB-dependent proinflammatory proteins. When
compared with sham-operated rats, livers and kidneys from rats
submitted to HS exhibited a significant increase in iNOS expression
(Figs. 7A, B, respectively). The treatment of HS rats with artesunate
at the onset of resuscitation significantly attenuated the iNOS
expression caused by HS in livers and kidneys (Figs. 7A, B).
Although there was a trend for an increase in 3-NT staining in
HS animals, we observed no significant difference in 3-NT staining
in liver or kidney in any of the groups (supplemental Fig. 3, http://
links.lww.com/SLA/A977).
When compared to sham-operated rats, HS rats treated with
vehicle developed significant increases in the serum levels of the
proinflammatory cytokines TNF-a (Fig. 7C) and IL-6 (Fig. 7D).
The treatment of HS rats with artesunate significantly attenuated
the increases in serum TNF-a and IL-6 caused by HS (Fig. 7C, D).
The treatment of sham rats with artesunate had no effect on serum
cytokine levels.
DISCUSSION
The main finding of the present report is that the antimalarial
drug artesunate attenuates the organ injury and dysfunction associ-
ated with HS. Administration of artesunate upon resuscitation
reduces the MOF by enhancing the resistance of organs against
injury/dysfunction by activating a well-known cell survival pathway
and by reducing excessive inflammation. The lower dose of artesu-
nate shown here to be effective in HS is identical to the dose used in
patients with malaria, many of which also have multiple organ
dysfunction. Indeed, in these patients artesunate is superior to
quinine in improving survival.6
In order to gain a better insight into the potential mechanism of
action of artesunate in HS, we carried out a controlled RNA-seq
transcriptome analysis of white blood cells. Pathway analysis of
genes showing differential expression in both sham and HS rats was
strongly enriched for AKT1 interactor genes. Although AKT1 itself
was not differentially expressed, this does not reflect protein activity
and a mechanistic model of the AKT1 core network-predicted AKT
activation, on the basis of downregulation of several proinflamma-
tory genes in the AKT core network that are known to be down-
regulated by AKT. These include IRAK1 and FOXO4. IRAK1
induces nuclear translocation of NF-kB and activator protein AP-
1, resulting in the production of TNF-a and IL-6.19 Downregulation
of IRAK1 is protective in ischemia/reperfusion injury.20 FOXO4
specifically activatesMMP9 expression in response to TNF-a, acting
as a convergence point of cytokine and growth factor signaling
pathways. Thus, inhibition (or downregulation as seen with artesu-
nate) of FOXO4 could provide a therapeutic target for inflammatory
arterial diseases.21
In our gene expression studies, we also observed a decrease in
gene expression of MEMO1 in sham-operated animals and in HS rats
(data not shown). This finding was somewhat contradictory to the
hypothesis of AKT activation, as the protein has been shown to
activate the Akt pathway.22 Subsequently, we have evaluated
MEMO1 by Western blot analysis and found a consistent increase
in MEMO1 protein, confirming that artesunate does indeed enhance
the expression of MEMO1 protein in liver/kidney of sham and HS
rats (data not shown). The observed reduction in MEMO1 transcript
expression may represent a feedback control mechanism.
We discovered that treatment of HS rats with artesunate
activates the kinase Akt,23 activation of which has beneficial effects
including reduction/prevention of i) ventilation-induced lung
injury,24 ii) sepsis-induced cardiac dysfunction,25 iii) sepsis-induced
acute kidney injury,26 iv) myocardial ischaemia-reperfusion,27 and v)
HS-induced organ dysfunction.28 Activation of Akt results in
FIGURE 4. Core network of AKT1 inter-
actor proteins constructed using Ingen-
uity pathway analysis. The network was
constructed using AKT1 as a seed and all
genes showing differential expression in
SH v SH þ ART and HS v HS þ ART
analysis. Ingenuity Molecule Activity Pre-
dictor analysis predicts activation of AKT1
on the basis of observed downregulation
in several interactors that are known to
be inhibited by AKT1. AKT1 indicates
Core network of AKT1 gene interactor
proteins; ART, artesunate; sham.
Sordi et al Annals of Surgery  Volume 265, Number 2, February 2017
412 | www.annalsofsurgery.com  2016 Wolters Kluwer Health, Inc. All rights reserved.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
phosphorylation and activation of eNOS at Ser117729 that enhances
the formation of small amounts of NO, which is pivotal for
the preservation of microvascular perfusion,30 reducing organ
injury.25,31
Activation of Akt was also associated with an increase in
phosphorylation of GSK-3b. Phosphorylation of the constitutively-
active, serine-threonine kinase GSK-3b by Akt turns off the
catalytic activity of GSK-3b23. Inhibition of GSK-3b reduces
inflammation32 and organ injury in myocardial ischemia,25 colitis,33
endotoxemia,34,35 and HS.36 Thus, activation of Akt/eNOS and
inactivation of GSK-3b may contribute to the beneficial effects of
artesunate in HS.
Inhibition of GSK-3b directly inhibits NF–kB-dependent gene
transcription,37 and NF-kB plays a pivotal role in inflammation38 and
FIGURE 5. Artesunate attenuates the activation of NF-kB pathway induced by HS in the liver. The phosphorylation of (A) Ser473 on
Akt, (B) Ser1177 on eNOS, (C) Ser9 on GSK-3b, and (E) the nuclear translocation of p65 subunit of NF-kB in the liver of sham and HS
rats treated with vehicle or artesunate (4.8mg/kg) on resuscitation were determined by Western blotting. Protein expression was
measured as relative OD, corrected for the corresponding b-actin or histone contents and normalized using the related sham band.
Data are presented as box and whiskers, showing medians, interquartile range, and full range (n ¼ 3–4 animals per group).
Statistical analysis was performed using Kruskal-Wallis test followed by Dunn post hoc test. P < 0.05 vs sham þ vehicle and
#P < 0.05 vs HS þ vehicle. OD indicates optical density.
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organ injury28,31,39. HS increased the translocation of subunit p65 to
the nucleus, indicating NF-kB activation. Treatment of HS rats with
artesunate caused inactivation of GSK-3b (phosphorylation), which
was associated with reduced nuclear translocation of p65. Indeed,
inhibition of NF-kB (by inhibiting activation of the Inhibitor of kappa
B kinase complex) reduces the organ injury/inflammation in HS.28
Thus, inhibition of GSK-3b and NF-kB may both importantly con-
tribute to the observed anti-inflammatory effects of artesunate in HS.
As NF-kB regulates iNOS expression and iNOS plays an
important role in the pathophysiology of HS,40,41 we have inves-
tigated the effects of artesunate on iNOS expression in HS rats. HS
increased the expression of iNOS in liver and kidney, and artesunate
FIGURE 6. Artesunate attenuates the activation of NF-kB pathway induced by HS in the kidney. The phosphorylation of (A) Ser473
on Akt, (B) Ser1177 on eNOS, (C) Ser9 on GSK-3b, and (E) the nuclear translocation of p65 subunit of NF-kB in the kidney of sham
andHS rats treatedwith vehicle or artesunate (4.8mg/kg) on resuscitationwere determined byWestern blotting. Protein expression
wasmeasured as relative optical density (OD), corrected for the corresponding b-actin or histone contents and normalized using the
related sham band. Data are presented as box and whiskers, showing medians, interquartile range and full range (n¼ 3–4 animals
per group). Statistical analysis was performed using Kruskal-Wallis test followed by Dunn post hoc test. #P < 0.05 vs HS þ vehicle.
OD indicates optical density.
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attenuated iNOS expression in both the organs. As an excessive
formation of NO by iNOS contributes to the organ injury in HS16,40
and sepsis,42,43,44 and also causes cellular damage and tissue injury
through peroxynitrite formation,41 the reduction in iNOS expression
may contribute to the organ protection afforded by artesunate.
However, we have not observed a significant difference in the degree
of staining for 3-NT among the groups. It is possible that iNOS
expression, NO production, NT formation, and nitration of proteins
occur at different stages after the onset of resuscitation. All of our
data were obtained at 4 hours after HS, and we speculate that iNOS
expression precedes any significant nitration of tyrosine residues
within proteins. It should be stressed that our data also demonstrate
that the protection afforded by artesunate is not secondary to a
reduction of peroxynitrite formation.
An increase circulating proinflammatory cytokines such as
TNF-a and IL-6 is associated with organ injury/dysfunction and
lethality after HS and sepsis.43,45,46,47 Elevated IL-6 concentrations
predict the development of MOF in patients with trauma-hemor-
rhage.48 We report here that HS results in the excessive formation of
TNF-a and IL-6, and that treatment of HS rats with artesunate
reduced the production of these cytokines. As patients who either
produce excessive amounts of cytokines or cannot clear them from
the circulation have an increased risk of MOF and death45; the
reduction of circulating TNF-a and IL-6 may have importantly
contributed to the attenuation of organ injury and dysfunction
observed in HS rats treated with artesunate.
Taken together, our results show that the protective effect of
artesunate in HS is associated with an increased activation of Akt and
eNOS phosphorylation and consequently inhibition of GSK-3b,
which in turn, inhibited the translocation of NF-kB to the nucleus.
This mechanism is supported on several levels. At a transcriptome
level using pathway analysis, we find strong support for AKT
activation on the basis of genome-wide enrichment of differential
expression among AKT interactors. Expression of proinflammatory,
inhibition targets of AKT, such as IRAK1 and FOXO4, are reduced.
At the protein level, artesunate also attenuated iNOS expression and
proinflammatory cytokines formation, all of which may have con-
tributed for the attenuation of MOF associated with HS. Thus, the use
FIGURE 7. Artesunate attenuates iNOS expression in liver and kidney and serum TNF-a and IL-6 induced by HS. The iNOS
expression in the liver (A) and kidney (B) of sham and HS rats treated with vehicle or artesunate (4.8mg/kg) on resuscitation were
determined byWestern blotting. Protein expression wasmeasured as relative OD, corrected for the corresponding b-actin contents
and normalized using the related sham band. The serum concentrations of (C) TNF-a and (D) IL-6 were determined by ELISA in
sham and HS rats treated with vehicle or artesunate (4.8mg/kg) on resuscitation. Data are presented as box and whiskers format
showingmedians, interquartile range, and full range (n¼ 8–10 animals per group). When necessary (TNF and IL-6 data) the values
had been transformed into logarithms to achieve normality and homogeneity of variances. Statistical analysis was performed using
2-way ANOVA followed by Bonferroni post hoc test. P < 0.05 vs sham þ vehicle and #P < 0.05 vs HS þ vehicle. ANOVA indicates
analysis of variance; ELISA, enzyme-linked immunosorbent assay; OD, optical density.
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of the antimalarial drug artesunate, which is a safe, low-cost and
already-developed drug, could represent a therapeutic approach for
the treatment and/or prevention of the MOF associated with HS.
Limitations of our study: We used an acute model of HS,
which leads to MOF and systemic inflammation within a few hours
of the onset of resuscitation. At this time point (4 h after resuscita-
tion) there is organ dysfunction, significant activation of the NF-kB
pathway and expression of NF–kB-dependent proteins. However,
although effective in this acute setting, we cannot conclude that
artesunate will have the same beneficial effect in animal models with
long-term follow-up. Future studies in large animals (as pigs) may be
useful to gain a better understanding of both efficacy and mechanism
of action of artesunate in HS. Also, the demonstration of a reduction
in mortality by means of such studies would have strengthened the
efficacy data with artesunate reported in our study. We report that the
administration of artesunate during resuscitation had no effect on
blood pressure indicating that the beneficial effects of artesunate in
HS may be independent of an increase in blood pressure/increase in
perfusion of vital organs. This may limit the effectiveness of arte-
sunate in HS, as other interventions may be necessary to overcome
the vascular decompensation associated with HS.
Currently, there is no specific treatment for organ failure/
dysfunction associated with HS, which is associated with a high
morbidity and mortality. Thus, a safe and low-cost therapeutic
intervention may have a great impact on the patient quality of life
and the costs of health care. The doses of artesunate used here are
very similar to those used in patients with malaria. Artesunate has a
very good safety profile with no or minimal adverse effects in both
healthy volunteers (up to 8mg/kg i.v.) and patients with severe
malaria. The excellent safety profile of artesunate is (at least in
part) due to its very short half-life in man: the intravenous injection of
artesunate results in high, transient peak concentrations, which
decline rapidly with an estimated half-life of 15 minutes. The
concentration of the active metabolite DHA peaks within 25 minutes
of injection of artesunate, and the half-life is estimated 30 to 60
minutes. Themetabolism of artesunate is not affected by the presence
of either renal or liver failure, and the dose of artesunate does not
need to be adjusted in patients with multiple organ failure.49 Thus, we
are planning a phase II placebo-controlled randomized clinical trial
designed to evaluate the effects of GMP-artesunate (2.4 or 4.8mg/kg
i.v.) in 105 patients with trauma and severe hemorrhage. This single-
center trial will commence at the Royal London Hospital in 2016.
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